JP4480400B2 - サリチルアニリド化合物、ポリマー成分および少なくとも１種の他の抗寄生虫化合物を含む持続性駆虫組成物 - Google Patents

サリチルアニリド化合物、ポリマー成分および少なくとも１種の他の抗寄生虫化合物を含む持続性駆虫組成物 Download PDF

Info

Publication number
JP4480400B2
JP4480400B2 JP2003570859A JP2003570859A JP4480400B2 JP 4480400 B2 JP4480400 B2 JP 4480400B2 JP 2003570859 A JP2003570859 A JP 2003570859A JP 2003570859 A JP2003570859 A JP 2003570859A JP 4480400 B2 JP4480400 B2 JP 4480400B2
Authority
JP
Japan
Prior art keywords
closantel
ivermectin
compound
composition
antiparasitic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003570859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525355A (ja
JP2005525355A5 (https=
Inventor
ブレイクリー，ウィリアム
クロミー，リリアン
ダフィー，ショーン
Original Assignee
ノルブルック ラボラトリーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノルブルック ラボラトリーズ リミテッド filed Critical ノルブルック ラボラトリーズ リミテッド
Publication of JP2005525355A publication Critical patent/JP2005525355A/ja
Publication of JP2005525355A5 publication Critical patent/JP2005525355A5/ja
Application granted granted Critical
Publication of JP4480400B2 publication Critical patent/JP4480400B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2003570859A 2002-02-28 2003-02-12 サリチルアニリド化合物、ポリマー成分および少なくとも１種の他の抗寄生虫化合物を含む持続性駆虫組成物 Expired - Lifetime JP4480400B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0204712A GB2386066A (en) 2002-02-28 2002-02-28 Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
PCT/GB2003/000645 WO2003072113A1 (en) 2002-02-28 2003-02-12 Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound

Publications (3)

Publication Number Publication Date
JP2005525355A JP2005525355A (ja) 2005-08-25
JP2005525355A5 JP2005525355A5 (https=) 2006-04-06
JP4480400B2 true JP4480400B2 (ja) 2010-06-16

Family

ID=9931978

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003570859A Expired - Lifetime JP4480400B2 (ja) 2002-02-28 2003-02-12 サリチルアニリド化合物、ポリマー成分および少なくとも１種の他の抗寄生虫化合物を含む持続性駆虫組成物

Country Status (23)

Country Link
US (1) US9289380B2 (https=)
EP (1) EP1478372B1 (https=)
JP (1) JP4480400B2 (https=)
AP (1) AP1977A (https=)
AR (1) AR038852A1 (https=)
AT (1) ATE347897T1 (https=)
AU (1) AU2003205887B2 (https=)
BR (1) BR0307974B1 (https=)
CA (1) CA2476520C (https=)
CO (1) CO5611154A2 (https=)
CR (1) CR7429A (https=)
CY (1) CY1107530T1 (https=)
DE (1) DE60310377T2 (https=)
DK (1) DK1478372T3 (https=)
EC (1) ECSP045320A (https=)
ES (1) ES2275076T3 (https=)
GB (1) GB2386066A (https=)
MX (1) MXPA04007996A (https=)
NZ (1) NZ534704A (https=)
PT (1) PT1478372E (https=)
SI (1) SI1478372T1 (https=)
WO (1) WO2003072113A1 (https=)
ZA (1) ZA200406782B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002952597A0 (en) * 2002-11-11 2002-11-28 Schering-Plough Pty. Limited Topical parasiticide formulations and methods of treatment
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CN1767815A (zh) 2003-03-31 2006-05-03 阿尔萨公司 非水单相载体和使用这类载体的制剂
US7666444B2 (en) 2004-02-02 2010-02-23 Wyeth Antiparasitic composition
WO2006061214A1 (en) * 2004-12-10 2006-06-15 Bayer Healthcare Ag Anthelmintic composition
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
FR2991173B1 (fr) 2012-06-04 2015-11-06 Virbac Composition veterinaire a administration cutanee a base d'oxyclozanide
CA2924537C (en) * 2013-09-30 2018-01-16 Todd P. Foster Long-acting spiro-isoxazoline formulations
EP3338783B1 (en) 2014-09-12 2024-01-24 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
RU2730996C2 (ru) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Системы установки и извлечения имплантата
GB201604484D0 (en) * 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950360A (en) 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
DE2263509C2 (de) 1972-12-27 1981-12-24 Rudolf Dr. 6380 Bad Homburg Kürner Deodorant
US4005218A (en) * 1975-03-18 1977-01-25 Janssen Pharmaceutica N.V. Antiparasitic salicylanilide derivatives
SE434277B (sv) * 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4199569A (en) * 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4206205A (en) * 1977-10-03 1980-06-03 Merck & Co., Inc. Monosaccharide and aglycone derivatives of C-076
US4173571A (en) * 1977-12-19 1979-11-06 Merck & Co., Inc. 13-Halo and 13-deoxy derivatives of C-076 compounds
US4171314A (en) * 1977-12-19 1979-10-16 Merck & Co., Inc. 13-Halo and 13-deoxy C-076 compounds
US4128632A (en) * 1978-02-13 1978-12-05 Merck & Co., Inc. Solubilization of Rafoxanide
NZ197796A (en) 1980-08-04 1984-11-09 Merck & Co Inc Stabilised aqueous formulations containing ivermectin
NZ210505A (en) 1983-12-22 1988-06-30 Merck & Co Inc Parasiticidal compositions containing avermectin or milbemycin derivatives
GB8727157D0 (en) * 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
NZ223200A (en) * 1988-01-15 1989-01-06 Ancare Distributors Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier
US5273805A (en) * 1991-08-05 1993-12-28 Minnesota Mining And Manufacturing Company Structured flexible carrier web with recess areas bearing a layer of silicone on predetermined surfaces
NZ335166A (en) 1999-04-14 2001-11-30 Ashmont Holdings Ltd Anthelmintic composition containing triclabendazole in at least one solvent
CN1054504C (zh) 1993-03-15 2000-07-19 科尔加特·帕尔莫利弗公司 洁牙剂
PL174488B1 (pl) 1993-05-10 1998-08-31 Merck & Co Inc Preparat do zwalczania pasożytów zwierząt oraz sposób wytwarzania preparatu do zwalczania pasożytów zwierząt
DE69432985D1 (de) 1993-06-15 2003-09-04 Australian Nat University Acto Synergistische anthelmintische zusammensetzungen gegen fasciola hepatica und andere fascola spezien
NZ248486A (en) * 1993-08-24 1996-07-26 Ashmont Holdings Limited Subst Stable anthelmintic formulation containing closantel and one or more avermectins or milbemycins in a glycol based solvent
AU698431B2 (en) * 1993-12-13 1998-10-29 Michael Hilary Burke Anthelmintic composition containing rafoxanide and fenbendazole
FR2739778B1 (fr) * 1995-10-13 1997-12-12 Virbac Lab Formulation topique destinee a traiter la maladie de la douve du foie chez l'animal
US5773422A (en) * 1996-01-29 1998-06-30 Komer; Gene Avermectin formulation
US6193989B1 (en) * 1997-03-21 2001-02-27 Biogenesis S.A. Long acting injectable parasiticidal composition and the process for its preparation
US6340672B1 (en) 2000-02-16 2002-01-22 Phoenix Scientific, Inc. Parasiticidal formulation and a method of making this formulation
AUPQ875700A0 (en) * 2000-07-13 2000-08-03 Reflex Research Limited Combination compositions
AUPR510001A0 (en) 2001-05-18 2001-06-14 Jupitar Pty Ltd Formulation and method

Also Published As

Publication number Publication date
AU2003205887B2 (en) 2007-02-15
CA2476520A1 (en) 2003-09-04
CY1107530T1 (el) 2013-03-13
EP1478372B1 (en) 2006-12-13
ZA200406782B (en) 2005-07-27
US20050118221A1 (en) 2005-06-02
JP2005525355A (ja) 2005-08-25
AU2003205887A1 (en) 2003-09-09
DE60310377T2 (de) 2007-10-31
US9289380B2 (en) 2016-03-22
EP1478372A1 (en) 2004-11-24
AP1977A (en) 2009-03-19
AP2004003142A0 (en) 2004-09-30
SI1478372T1 (sl) 2007-04-30
AR038852A1 (es) 2005-01-26
GB0204712D0 (en) 2002-04-17
ECSP045320A (es) 2004-11-26
CA2476520C (en) 2009-08-11
MXPA04007996A (es) 2004-11-26
WO2003072113A1 (en) 2003-09-04
ATE347897T1 (de) 2007-01-15
NZ534704A (en) 2007-02-23
GB2386066A (en) 2003-09-10
CR7429A (es) 2006-02-06
BR0307974A (pt) 2004-12-21
DE60310377D1 (de) 2007-01-25
ES2275076T3 (es) 2007-06-01
PT1478372E (pt) 2007-01-31
CO5611154A2 (es) 2006-02-28
BR0307974B1 (pt) 2014-10-21
DK1478372T3 (da) 2007-04-10

Similar Documents

Publication Publication Date Title
JP4480400B2 (ja) サリチルアニリド化合物、ポリマー成分および少なくとも１種の他の抗寄生虫化合物を含む持続性駆虫組成物
EP0427582A2 (en) Non-aqueous micellar solutions of various drugs
AU2008282388A1 (en) Endoparasiticidal topical compositions
CN106132409B (zh) 稳定的兽用驱虫制剂
JP4677405B2 (ja) 駆虫組成物
WO2003072112A1 (en) 'long'-'acting' injectable parasiticidal composition
CN121941412A (zh) 大环内酯的抗寄生虫组合物
HK1096621B (en) Parasiticidal composition

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20041027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100302

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100316

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130326

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4480400

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090826

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130326

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140326

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term